Oculis Holding AG (NASDAQ:OCS) Stock Rated “Moderate Buy” by Wall Street Brokerages

Oculis Holding AG (NASDAQ:OCS) has received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $39.44.

A number of research analysts recently weighed in on OCS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a research note on Thursday. Wall Street Zen raised shares of Oculis from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. lowered their price target on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Finally, HC Wainwright boosted their target price on Oculis from $26.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, September 18th.

Oculis Trading Up 0.4%

Shares of NASDAQ:OCS opened at $7.32 on Tuesday. The company has a market capitalization of $424.41 million, a PE ratio of -4.21 and a beta of 0.62. Oculis has a 12-month low of $7.11 and a 12-month high of $34.47. The business has a 50 day moving average of $10.65 and a two-hundred day moving average of $16.28. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. The business had revenue of $0.38 million during the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. As a group, analysts forecast that Oculis will post -2.01 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OCS. Braidwell LP acquired a new position in Oculis during the 2nd quarter worth about $11,570,000. Bank of America Corp DE boosted its holdings in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after buying an additional 5,813 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Oculis by 326.4% during the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after purchasing an additional 47,158 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Oculis during the first quarter worth approximately $776,000. Finally, Himension Capital Singapore PTE. LTD. acquired a new stake in Oculis during the 1st quarter worth approximately $503,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis (NASDAQ: OCS) is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis’ pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease.